{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:01:17Z","timestamp":1784782877184,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Anti-Ro52\/tripartite motif-containing protein 21 (TRIM21) IgG is one of the most common autoantibodies found in systemic autoimmune diseases and is typically found in conjunction with anti-Ro60 and\/or anti-La. A retrospective, cross-sectional study was undertaken to examine the clinical and laboratory features of two serological subsets: patients with anti-Ro52\/TRIM21 autoantibodies in the absence of anti-Ro60 and anti-La (isolated anti-Ro52\/TRIM21) and patients with anti-Ro52\/TRIM21 in the presence of anti-Ro60 and\/or anti-La.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Over a 12-month period, patients tested positive for anti-Ro52\/TRIM21 via line immunoassay (LIA) at the Westmead Hospital (Australia) immunopathology laboratory were included. The presence of anti-Ro60 and\/or anti-La via same LIA was noted. Associated laboratory and medical records were perused to extract demographic, laboratory, and clinical information.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 346 patients within the study period, and 39.9% of the patients positive for anti-Ro52\/TRIM21 lacked anti-Ro60\/anti-La autoantibodies. Isolated anti-Ro52\/TRIM21 patients tend to be older, have lower anti-Ro52\/TRIM21 titres, have lower rheumatoid factors, and have lower proportions of neutropaenia compared to patients who were positive for anti-Ro52\/TRIM21 and anti-Ro60\/La. This occurred independent to diagnoses of Sj\u00f6gren\u2019s syndrome or systemic lupus erythematosus. Coexisting neurological syndromes, pulmonary pathologies, and malignancies were more prevalent in the isolated anti-Ro52\/TRIM21 subset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with isolated anti-Ro52\/TRIM21 tend to have distinct and important clinical and laboratory associations. It is unclear if these patients evolve or remain a stable subset and how they originate immunologically. Longitudinal and prospective studies are required to ascertain the overall predictive and prognostic value of this stratification.<jats:table-wrap><jats:table><jats:tbody><jats:tr><jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Anti-Ro52\/TRIM21 is an autoantibody found in autoimmunity and non-immunological conditions.<\/jats:italic><jats:italic>\u2022 Sixty percent of anti-Ro52\/TRIM21 patients are positive for anti-Ro60.<\/jats:italic><jats:italic>\u2022 Isolated anti-Ro52\/TRIM21 has reduced anti-Ro52\/TRIM21 and rheumatoid factor titres.<\/jats:italic><jats:italic>\u2022 Isolated anti-Ro52\/TRIM21 is associated with anaemia and malignancies.<\/jats:italic><\/jats:td><\/jats:tr><\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p><\/jats:sec>","DOI":"10.1007\/s10067-022-06299-5","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T21:02:34Z","timestamp":1658610154000},"page":"3495-3501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Anti-Ro52\/TRIM21 serological subsets identify differential clinical and laboratory parameters"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-4803","authenticated-orcid":false,"given":"Adrian Y. S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne H.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"6299_CR1","doi-asserted-by":"publisher","unstructured":"Jones EL, Laidlaw SM, Dustin LB (2021) TRIM21\/Ro52 - roles in innate immunity and autoimmune disease. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.738473","DOI":"10.3389\/fimmu.2021.738473"},{"key":"6299_CR2","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00296-017-3718-1","volume":"37","author":"AYS Lee","year":"2017","unstructured":"Lee AYS (2017) A review of the role and clinical utility of anti-Ro52\/TRIM21 in systemic autoimmunity. Rheumatol Int 37:1323\u20131333. https:\/\/doi.org\/10.1007\/s00296-017-3718-1","journal-title":"Rheumatol Int"},{"key":"6299_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/03009742.2021.1887927","volume":"50","author":"AYS Lee","year":"2021","unstructured":"Lee AYS, Patterson KA, Tan DJ, Wilson ME, Proudman SM, Stevens W et al (2021) Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients. Scand J Rheumatol 50:469\u2013474. https:\/\/doi.org\/10.1080\/03009742.2021.1887927","journal-title":"Scand J Rheumatol"},{"key":"6299_CR4","doi-asserted-by":"publisher","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","volume":"172","author":"X Xing","year":"2020","unstructured":"Xing X, Li A, Li C (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134. https:\/\/doi.org\/10.1016\/j.rmed.2020.106134","journal-title":"Respir Med"},{"key":"6299_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.aac7442","volume":"350","author":"T Hung","year":"2015","unstructured":"Hung T, Pratt GA, Sundararaman B, Townsend MJ, Chaivorapol C, Bhangale T et al (2015) The Ro60 autoantigen binds endogenous retroelements and regulates inflammatory gene expression. Science 350:455\u2013459. https:\/\/doi.org\/10.1126\/science.aac7442","journal-title":"Science"},{"key":"6299_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev.biochem.71.090501.150003","volume":"71","author":"SL Wolin","year":"2002","unstructured":"Wolin SL, Cedervall T (2002) The La protein. Annu Rev Biochem 71:375\u2013403. https:\/\/doi.org\/10.1146\/annurev.biochem.71.090501.150003","journal-title":"Annu Rev Biochem"},{"key":"6299_CR7","doi-asserted-by":"publisher","unstructured":"Fabini G, Rutjes SA, Zimmermann C, Pruijn GJM, Steiner G (2000) Analysis of the molecular composition of Ro ribonucleoprotein complexes. 267:2778-2789. https:\/\/doi.org\/10.1046\/j.1432-1327.2000.01298.x","DOI":"10.1046\/j.1432-1327.2000.01298.x"},{"key":"6299_CR8","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.4049\/jimmunol.157.8.3694","volume":"157","author":"CL Keech","year":"1996","unstructured":"Keech CL, Gordon TP, McCluskey J (1996) The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J Immunol 157:3694\u20133699","journal-title":"J Immunol"},{"key":"6299_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.61.10.929","volume":"61","author":"I Peene","year":"2002","unstructured":"Peene I, Meheus L, De Keyser S, Humbel R, Veys EM, De Keyser F (2002) Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 61:929\u2013933. https:\/\/doi.org\/10.1136\/ard.61.10.929","journal-title":"Ann Rheum Dis"},{"key":"6299_CR10","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.jaut.2021.102724","volume":"124","author":"AYS Lee","year":"2021","unstructured":"Lee AYS, Reed JH, Gordon TP (2021) Anti-Ro60 and anti-Ro52\/TRIM21: Two distinct autoantibodies in systemic autoimmune diseases. J Autoimmun 124:102724. https:\/\/doi.org\/10.1016\/j.jaut.2021.102724","journal-title":"J Autoimmun"},{"key":"6299_CR11","doi-asserted-by":"publisher","unstructured":"Hervier B, Rimbert M, Colonna F, Hamidou MA, Audrain M (2009) Clinical significance of anti-Ro\/SSA-52 kDa antibodies\u2014a retrospective monocentric study. Rheumatology (Oxford) 48:964-7. https:\/\/doi.org\/10.1093\/rheumatology\/kep145%JRheumatology","DOI":"10.1093\/rheumatology\/kep145%JRheumatology"},{"key":"6299_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/jalm\/jfab104","volume":"7","author":"AYS Lee","year":"2022","unstructured":"Lee AYS, Brown DA, McDonald D, Lin MW (2022) Longitudinal tracking of extractable nuclear antigen (ENA) antibodies in a quaternary hospital laboratory cohort reveal dynamic antibody profiles. J Appl Lab Med 7:26\u201335","journal-title":"J Appl Lab Med"},{"key":"6299_CR13","first-page":"686","volume":"30","author":"S Retamozo","year":"2012","unstructured":"Retamozo S, Akasbi M, Brito-Zer\u00f3n P, Bosch X, Bove A, Perez-de-Lis M et al (2012) Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sj\u00f6gren's syndrome. Clin Exp Rheumatol 30:686\u2013692","journal-title":"Clin Exp Rheumatol"},{"key":"6299_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214202","volume":"14","author":"PD Burbelo","year":"2019","unstructured":"Burbelo PD, Gordon SM, Waldman M, Edison JD, Little DJ, Stitt RS et al (2019) Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS ONE 14:e0214202. https:\/\/doi.org\/10.1371\/journal.pone.0214202","journal-title":"PLoS ONE"},{"key":"6299_CR15","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/art.39214","volume":"67","author":"E Theander","year":"2015","unstructured":"Theander E, Jonsson R, Sj\u00f6str\u00f6m B, Brokstad K, Olsson P, Henriksson G (2015) Prediction of Sj\u00f6gren\u2019s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 67:2427\u20132436. https:\/\/doi.org\/10.1002\/art.39214","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 126","key":"6299_CR16","first-page":"134","volume":"38","author":"E Zampeli","year":"2020","unstructured":"Zampeli E, Mavrommati M, Moutsopoulos HM, Skopouli FN (2020) Anti-Ro52 and\/or anti-Ro60 immune reactivity: autoantibody and disease associations. Clin Exp Rheumatol 38(Suppl 126):134\u2013141","journal-title":"Clin Exp Rheumatol"},{"key":"6299_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2249.1998.00504.x","volume":"111","author":"M Rischmueller","year":"1998","unstructured":"Rischmueller M, Lester S, Chen Z, Champion G, Van Den Berg R, Beer R et al (1998) HLA class II phenotype controls diversification of the autoantibody response in primary Sj\u00f6gren\u2019s syndrome (pSS). Clin Exp Immunol 111:365\u2013371. https:\/\/doi.org\/10.1046\/j.1365-2249.1998.00504.x","journal-title":"Clin Exp Immunol"},{"key":"6299_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/03009742.2020.1732461","volume":"50","author":"AYS Lee","year":"2021","unstructured":"Lee AYS, Nissen MJ, Beroukas D, Ahern MJ, Barbara JA (2021) Detectable anti-proteinase-3 antibodies precede clinical manifestations in a case of anti-neutrophil cytoplasmic antibody-associated vasculitis. Scand J Rheumatol 50:76\u201377. https:\/\/doi.org\/10.1080\/03009742.2020.1732461","journal-title":"Scand J Rheumatol"},{"key":"6299_CR19","doi-asserted-by":"publisher","unstructured":"Robbins A, Hentzien M, Toquet S, Didier K, Servettaz A, Pham B-N et al (2019) Diagnostic utility of separate anti-Ro60 and anti-Ro52\/TRIM21 antibody detection in autoimmune diseases. Front Immunol 10. https:\/\/doi.org\/10.3389\/fimmu.2019.00444","DOI":"10.3389\/fimmu.2019.00444"},{"key":"6299_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/CLEP.S47399","volume":"6","author":"R Patel","year":"2014","unstructured":"Patel R, Shahane A (2014) The epidemiology of Sj\u00f6gren\u2019s syndrome. Clin Epidemiol 6:247\u2013255. https:\/\/doi.org\/10.2147\/CLEP.S47399","journal-title":"Clin Epidemiol"},{"key":"6299_CR21","first-page":"153","volume":"17","author":"S Stefanidou","year":"2013","unstructured":"Stefanidou S, Gerodimos C, Benos A, Galanopoulou V, Chatziyannis I, Kanakoudi F et al (2013) Clinical expression and course in patients with late onset systemic lupus erythematosus. Hippokratia 17:153\u2013156","journal-title":"Hippokratia"},{"key":"6299_CR22","first-page":"79","volume":"16","author":"Z Taha","year":"2021","unstructured":"Taha Z, Elgenaid SN, Essa MEA, Ahmed AA (2021) Guillain\u2013Barr\u00e9 syndrome as the first presentation in a patient with systemic lupus erythromatous; case report. Int J Clin Rheumtol 16:79\u201383","journal-title":"Int J Clin Rheumtol"},{"key":"6299_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cca.2021.07.006","volume":"521","author":"DP Bogdanos","year":"2021","unstructured":"Bogdanos DP, Gkoutzourelas A, Papadopoulos V, Liaskos C, Patrikiou E, Tsigalou C et al (2021) Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer. Clin Chim Acta 521:199\u2013205. https:\/\/doi.org\/10.1016\/j.cca.2021.07.006","journal-title":"Clin Chim Acta"},{"key":"6299_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/08916934.2012.732131","volume":"46","author":"A Men\u00e9ndez","year":"2013","unstructured":"Men\u00e9ndez A, G\u00f3mez J, Escanlar E, Caminal-Montero L, Mozo L (2013) Clinical associations of anti-SSA\/Ro60 and anti-Ro52\/TRIM21 antibodies: diagnostic utility of their separate detection. Autoimmunity 46:32\u201339. https:\/\/doi.org\/10.3109\/08916934.2012.732131","journal-title":"Autoimmunity"},{"key":"6299_CR25","first-page":"114","volume":"10","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Wang Y, Yun D, Huang Q, Meng D, Li Q et al (2020) TRIM21 overexpression promotes tumor progression by regulating cell proliferation, cell migration and cell senescence in human glioma. Am J Cancer Res 10:114\u2013130","journal-title":"Am J Cancer Res"},{"key":"6299_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","volume":"10","author":"P Ghillani","year":"2011","unstructured":"Ghillani P, Andr\u00e9 C, Toly C, Rouquette AM, Bengoufa D, Nicaise P et al (2011) Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: results of a multicentric study. Autoimmun Rev 10:509\u2013513. https:\/\/doi.org\/10.1016\/j.autrev.2011.03.004","journal-title":"Autoimmun Rev"},{"key":"6299_CR27","doi-asserted-by":"publisher","unstructured":"Murng SHK, Thomas M (2018) Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases. J Clin Pathol 71:12-9. https:\/\/doi.org\/10.1136\/jclinpath-2015-203587","DOI":"10.1136\/jclinpath-2015-203587"},{"key":"6299_CR28","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaut.2012.07.003","volume":"39","author":"G Arentz","year":"2012","unstructured":"Arentz G, Thurgood LA, Lindop R, Chataway TK, Gordon TP (2012) Secreted human Ro52 autoantibody proteomes express a restricted set of public clonotypes. J Autoimmun 39:466\u2013470. https:\/\/doi.org\/10.1016\/j.jaut.2012.07.003","journal-title":"J Autoimmun"},{"key":"6299_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaut.2017.01.004","volume":"79","author":"JH Reed","year":"2017","unstructured":"Reed JH, Gorny MK, Li L, Cardozo T, Buyon JP, Clancy RM (2017) Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus. J Autoimmun 79:99\u2013104. https:\/\/doi.org\/10.1016\/j.jaut.2017.01.004","journal-title":"J Autoimmun"},{"key":"6299_CR30","doi-asserted-by":"publisher","first-page":"20140238","DOI":"10.1098\/rstb.2014.0238","volume":"370","author":"CJH Dunand","year":"2015","unstructured":"Dunand CJH, Wilson PC (2015) Restricted, canonical, stereotyped and convergent immunoglobulin responses. Philos Trans R Soc Lond B Biol Sci 370:20140238. https:\/\/doi.org\/10.1098\/rstb.2014.0238","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"6299_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.molmed.2021.02.003","volume":"27","author":"SG Williams","year":"2021","unstructured":"Williams SG, Wolin SL (2021) The autoantigen repertoire and the microbial RNP world. Trends Mol Med 27:422\u2013435. https:\/\/doi.org\/10.1016\/j.molmed.2021.02.003","journal-title":"Trends Mol Med"},{"key":"6299_CR32","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.3389\/fimmu.2019.02845","volume":"10","author":"AYS Lee","year":"2019","unstructured":"Lee AYS, Chataway T, Colella AD, Gordon TP, Wang JJ (2019) Quantitative mass spectrometric analysis of autoantibodies as a paradigm shift in autoimmune serology. Front Immunol 10:2845. https:\/\/doi.org\/10.3389\/fimmu.2019.02845","journal-title":"Front Immunol"},{"key":"6299_CR33","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1074\/mcp.RA120.002314","volume":"20","author":"H Qi","year":"2021","unstructured":"Qi H, Ma M, Hu C, Xu Z-w, Wu F-l, Wang N et al (2021) Antibody binding epitope mapping (AbMap) of hundred antibodies in a single run. Mol Cell Proteomics 20:100059. https:\/\/doi.org\/10.1074\/mcp.RA120.002314","journal-title":"Mol Cell Proteomics"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06299-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T12:33:38Z","timestamp":1676205218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06299-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6299"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06299-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"26 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}